Sentences with phrase «for central nervous system disorders»

His main research focus and clinical interest is fluid biomarkers for central nervous system disorders including Alzheimer's disease, for which he has developed new diagnostic tests.

Alkermes is a commercial - stage company that focuses on drugs for central nervous system disorders, and could have some major catalysts in 2018.

Not exact matches

For example, MethylGene Inc. (TSX: MYG) is focusing on cancer treatment, biOasis Technologies Inc. (TSXV: BTI) is pursuing research on disorders of the central nervous system, and Cipher Pharmaceuticals Inc. (TSX: DND) is working on a treatment for acne - related conditioFor example, MethylGene Inc. (TSX: MYG) is focusing on cancer treatment, biOasis Technologies Inc. (TSXV: BTI) is pursuing research on disorders of the central nervous system, and Cipher Pharmaceuticals Inc. (TSX: DND) is working on a treatment for acne - related conditiofor acne - related conditions.

The clinical - stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life - altering central nervous system (CNS) disorders, SAGE Therapeutics Inc. (NASDAQ: SAGE) seem to be poised for a price surge as per its latest charts.

Palm Oil - Derived Natural Vitamin E a-Tocotrienol in Brain Health and Disease: Scientific literature evaluating the therapeutic potential of tocotrienols (type of vitamin E found in abundance in palm fruit oil) for neurodegenerative disorders of the central nervous system, cancer treatment, and hypercholesterolemia.

A team of researchers at the University of Central Florida is using breakthrough gene - editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system.

That can help us both recognize fibromyalgia for what it is — a disorder of the central nervous system — and treat it more effectively.»

The N2B patch project is supported financially by the EU within the scope of the tender procedure «Biomaterials for diagnosis and treatment of demyelination disorders of the central nervous system.»

The study of almost 8,000 families, published today (21 March) in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

According to Miller, «This work suggests that enhanced vesicular filling can be sustained over time and may be a viable therapeutic approach for a variety of central nervous system disorders that involve the storage and release of dopamine, serotonin, or norepinephrine.»

Ritalin, the brand name for methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder, is a growing problem among college students who use it without a prescription as a so - called «study enhancer.»

«We are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness,» said Bioquark CEO Ira Pastor.

Most recently, Dr. Gringeri was the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a Netherlands - based company engaged in human gene therapies for orphan diseases related to metabolic disorders, liver diseases, blood diseases, and disorders of the central and peripheral nervous systems.

The study of almost 8,000 families, published in Nature, found for the first time that mutations outside of genes can cause rare developmental disorders of the central nervous system.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Simply put, both disorders prevent normal development of the central nervous system, resulting in premature death in children, presenting an urgent need for effective therapeutic intervention.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria

Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.

However, they say the work at least proves the potential for mRNA therapy to successfully treat not only hemophilia B but also other human disorders, such as hemophilia A (caused by faulty clotting factor VIII) or a variety of diseases of the liver, central nervous system, lung and eyes.

The endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.

n a survey, the four top reasons for people quitting coffee were: central nervous system disorders, 39 %; gastrointestinal problems, 37 %; to break the addiction, 19 %; and fibrocystic breast tumors, 15 %.

Categories: Amino Acids, Amino Acids for Health Issues, GABA, Glutamic Acid, Glycine, Mental Health, Non-Essential Amino Acids Tags: amino acid, amino acid information center, calm, calming, central nervous system, GABA, gamma - aminobutyric acid, glutamate, glutamic acid, glycine, natural ingredients, nercous, nerves, nervous system, neuropsychiatric disorders, pharmaceutical drugs, schizophrenia, treat schizophrenia, zorilla marketing August 26, 2015 Author AAIADMIN

It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Not an approved drug for cats Young, growing animals due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Breeding, pregnant or nursing animals Pets who have a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones Directions:

Young, growing animals due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Should not be used at high doses in cats (may cause blindness) Breeding, pregnant or nursing animals Pets who have a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones and / or sulfonamides Directions:

The Animal Neurology & Imaging Center is dedicated to providing exceptional patient and client care via comprehensive, state - of - the - art diagnostics and treatments for small animals with disorders of the central and peripheral nervous systems.

Young, growing dogs due to potential for cartilage abnormalities Use with caution in animals with liver or kidney conditions, or those suffering dehydration Breeding, pregnant or nursing animals Use with caution in cats at high doses Use with caution in pets with a history of seizures or other central nervous system disorders Pets known to have had an allergic reaction to other quinolones Directions:

This is important as certain medical conditions [e.g., endocrine disorders / thyroid problems, central nervous system diseases, drug - related conditions, infectious disease, sleep - related disorders] should be differentiated from a mental health condition to avoid misdiagnosis and improper treatment for your condition.

Parkinson's disease is a degenerative disorder of the central nervous system named for James Parkinson (1755 - 1824), the physician who first described it in 1817.

For example, suffering childhood adversity, using cannabis, and having childhood viral infections of the central nervous system, all increase the odds of someone being diagnosed with a psychotic disorder (such as schizophrenia) by around two to threefold.